作者: IRATE 時(shí)間: 2025-3-21 22:03 作者: 非實(shí)體 時(shí)間: 2025-3-22 00:26 作者: 諂媚于人 時(shí)間: 2025-3-22 06:08
Viral Protease Inhibitors,hese have made the most significant advances in the recent past. Thus, we discuss the biochemistry of HIV-1 protease, inhibitor development, clinical use of inhibitors, and evolution of resistance. Since many different viruses encode essential proteases, it is possible to envision the development of作者: 妨礙 時(shí)間: 2025-3-22 08:50
Anti-Influenza Drugs: The Development of Sialidase Inhibitors, annum as a result of viral infections alone. The scourge of influenza virus has plagued mankind throughout the ages. The fact that new viral strains emerge on a regular basis, particularly out of Asia, establishes a continual socio-economic threat to mankind. The arrival of the highly pathogenic av作者: 解開(kāi) 時(shí)間: 2025-3-22 15:41 作者: angina-pectoris 時(shí)間: 2025-3-22 18:36
Inhibitors of Viral Entry,rs exert their biological properties by inhibiting protein—protein interactions either within the viral envelope (Env) glycoproteins or between viral Env and host-cell receptors. The nature of resistance to entry inhibitors also differs from compounds inhibiting enzymatic targets due to their differ作者: 車床 時(shí)間: 2025-3-23 01:07
Interferons and Their Use in Persistent Viral Infections,ned, fully sequenced and IFN-α was produced in recombinant form. Recombinant IFN-α is now used as the basis for treatment of chronic hepatitis C virus infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, al作者: 青石板 時(shí)間: 2025-3-23 04:00
Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses,nse oligonucleotides, ribozymes, DNAzymes, and aptamers can be designed to trigger the sequence-specific inhibition of particular mRNA transcripts, including viral genomes. However, difficulties with their efficiency, off-target effects, toxicity, delivery, and stability halted the development of nu作者: 陶器 時(shí)間: 2025-3-23 08:41 作者: Hectic 時(shí)間: 2025-3-23 12:54 作者: enchant 時(shí)間: 2025-3-23 15:33 作者: deriver 時(shí)間: 2025-3-23 20:26
Socio-Economic Impact of Antiviral Intervention,tween provider costs, direct household costs, and indirect costs. There is a growing number of publications on provider costs in different countries, but the methodology and the degree of precision between these papers make it difficult to give a good estimate of the current provider costs of treati作者: ablate 時(shí)間: 2025-3-24 00:58 作者: 蝕刻 時(shí)間: 2025-3-24 06:01 作者: 夾死提手勢(shì) 時(shí)間: 2025-3-24 10:01 作者: PAEAN 時(shí)間: 2025-3-24 14:39 作者: infarct 時(shí)間: 2025-3-24 18:52 作者: BUMP 時(shí)間: 2025-3-24 19:43 作者: Cultivate 時(shí)間: 2025-3-25 03:04 作者: V切開(kāi) 時(shí)間: 2025-3-25 06:04 作者: 上漲 時(shí)間: 2025-3-25 07:29 作者: Pedagogy 時(shí)間: 2025-3-25 12:37 作者: 蚊子 時(shí)間: 2025-3-25 19:17
Lecture Notes in Computer Sciencers exert their biological properties by inhibiting protein—protein interactions either within the viral envelope (Env) glycoproteins or between viral Env and host-cell receptors. The nature of resistance to entry inhibitors also differs from compounds inhibiting enzymatic targets due to their differ作者: 無(wú)法取消 時(shí)間: 2025-3-25 22:25 作者: 榮幸 時(shí)間: 2025-3-26 00:30 作者: FRAX-tool 時(shí)間: 2025-3-26 06:03
Lecture Notes in Computer Scienceal infections such as hepatitis B or C and HIV infection. Two basic gene therapy strategies are introduced here. The first involves the expression of a protein or an RNA that inhibits viral replication by targeting crucial steps of the viral life cycle or by interfering with a cellular factor requir作者: 詩(shī)集 時(shí)間: 2025-3-26 11:53
Muhammad Afzal,Panos Panagiotopouloss of antiviral resistance development are discussed for specific compounds or drug classes in the previous chapters, while this chapter provides an overview regarding the evolution of different viruses (HIV, HBV, HCV, and Influenza) under pressure of antiviral therapy. Virus replication is an error 作者: 調(diào)味品 時(shí)間: 2025-3-26 16:00
Jeremy Rose,Jesper Holgersson,Eva S?derstr?mral illnesses, namely hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). There is no doubt that most current knowledge about combination antiviral therapy has been developed in the battle against HIV. The availability of more than 20 antiretroviral drugs has pe作者: Predigest 時(shí)間: 2025-3-26 17:56 作者: 社團(tuán) 時(shí)間: 2025-3-26 21:35 作者: Dorsal-Kyphosis 時(shí)間: 2025-3-27 01:28 作者: Ethics 時(shí)間: 2025-3-27 05:47
https://doi.org/10.1007/11545156 infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections.作者: gimmick 時(shí)間: 2025-3-27 12:41 作者: 善變 時(shí)間: 2025-3-27 17:15 作者: Neonatal 時(shí)間: 2025-3-27 18:48 作者: novelty 時(shí)間: 2025-3-27 23:23
Lecture Notes in Computer Sciencee cycles and, in the context of HIV treatment, contributes to the growing armamentarium of antivirals which, in multidrug combinations, can effectively inhibit viral replication and prevent disease progression.作者: 火光在搖曳 時(shí)間: 2025-3-28 02:38 作者: Lice692 時(shí)間: 2025-3-28 08:59
Jeremy Rose,Jesper Holgersson,Eva S?derstr?mpidly and will provide further opportunities to explore the efficacy of combination antiviral therapy. While sufficient suppression of HIV RNA and HBV DNA can only be achieved by long-term administration of potent antiviral drugs, HCV RNA may be completely eradicated from the infected individual after a limited duration of treatment.作者: 腐敗 時(shí)間: 2025-3-28 13:52
Approaches for the Development of Antiviral Compounds: The Case of Hepatitis C Virus,in Phases 1, 2, and 3, leading to the goal of approved drugs that benefit the infected individual. This review uses hepatitis C virus (HCV), for which we still do not have an ideal therapeutic modality, as an example of the multidisciplinary efforts needed to discover new antiviral drugs for the benefit of humanity.作者: languor 時(shí)間: 2025-3-28 15:01
Inhibitors of Viral Entry,e cycles and, in the context of HIV treatment, contributes to the growing armamentarium of antivirals which, in multidrug combinations, can effectively inhibit viral replication and prevent disease progression.作者: 反感 時(shí)間: 2025-3-28 21:45
Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses,eic acid-based therapeutics. Antiviral RNAi approaches are highly effective in vitro and in animal models and are currently being tested in clinical trials. Here we give an overview of antiviral nucleic acid-based therapeutics. We focus on antisense and RNAi-based compounds that have been shown to be effective in animal model systems.作者: 中世紀(jì) 時(shí)間: 2025-3-29 01:48 作者: 尖 時(shí)間: 2025-3-29 07:01 作者: dowagers-hump 時(shí)間: 2025-3-29 07:51 作者: 消耗 時(shí)間: 2025-3-29 12:13
Maria A. Wimmer,Hans J. Scholl,Enrico Ferron grew that these pathogens had more than one Achilles heel that might be suitable targets for small molecules with antiviral activity. This chapter addresses those “other” targets as well as other approaches to the tried and tested polymerase inhibitors, the so-called non-nucleoside inhibitors of reverse transcriptase.作者: 天然熱噴泉 時(shí)間: 2025-3-29 15:58
Other Inhibitors of Viral Enzymes and Functions,n grew that these pathogens had more than one Achilles heel that might be suitable targets for small molecules with antiviral activity. This chapter addresses those “other” targets as well as other approaches to the tried and tested polymerase inhibitors, the so-called non-nucleoside inhibitors of reverse transcriptase.作者: orient 時(shí)間: 2025-3-29 23:25
Antiviral Strategies,ecome increasingly successful. Novel strategies currently explored in basic research or preclinical studies include approaches targeting host factors important for virus replication, the exploitation of the innate immune response system as well as the use of gene silencing strategies aimed at interf作者: Chagrin 時(shí)間: 2025-3-30 00:47 作者: 無(wú)法取消 時(shí)間: 2025-3-30 06:09
Viral Protease Inhibitors,velopment is most advanced for hepatitis C virus (HCV), and we also provide a review of HCV NS3/4A serine protease inhibitor development, including combination therapy and resistance. Finally, we discuss other viral proteases as potential drug targets, including those from Dengue virus, cytomegalovi
